Literature DB >> 9374383

Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions.

H J Bontkes1, T D de Gruijl, J M Walboomers, A J van den Muysenberg, A W Gunther, R J Scheper, C J Meijer, J A Kummer.   

Abstract

Cervical carcinomas are closely associated with high-risk human papillomavirus (HPV) types and are preceded by cervical intraepithelial neoplasia (CIN). Most CIN lesions regress spontaneously and will not evolve to invasive carcinoma. The cellular immune system mediated by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are thought to play an important role in the ultimate decline of CIN lesions. Although TIA-1 is constitutively expressed in the majority of circulating T cells and defines a subpopulation of CD8+ T cells with cytotoxic potential, granzyme B is only expressed in CTLs upon activation. In the present study we have evaluated the expression of these proteins by lymphocytes present in 24 randomly chosen CIN lesions with increasing degree of atypia and in 14 cervical squamous cell carcinomas. As major histocompatibility complex (MHC) class I expression is frequently down-regulated in HPV-induced lesions, thus possibly frustrating tumour cell recognition by infiltrating CTLs, these lesions were also analysed for MHC class I expression. The results indicated that in most CIN lesions only a minority of CTLs are activated, whereas in some carcinomas a massive infiltration of activated, i.e. granzyme B-positive, CTLs were observed. The percentage of activated CTLs was not related to expression of MHC class I on neoplastic cells. These results suggest that in some carcinomas proper activation of CTLs occurs but that most likely local factors or immunoselection of resistant neoplastic cells inhibit a proper response of CTLs to these neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374383      PMCID: PMC2228142          DOI: 10.1038/bjc.1997.560

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  BCL-2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma.

Authors:  B Ter Harmsel; F Smedts; J Kuijpers; M Jeunink; B Trimbos; F Ramaekers
Journal:  J Pathol       Date:  1996-05       Impact factor: 7.996

2.  Resistance of CTL to perforin-mediated lysis. Evidence for a lymphocyte membrane protein interacting with perforin.

Authors:  C Müller; J Tschopp
Journal:  J Immunol       Date:  1994-09-15       Impact factor: 5.422

3.  Absence of HLA class I expression by Reed-Sternberg cells.

Authors:  S Poppema; L Visser
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

Review 4.  TIA-1: structural and functional studies on a new class of cytolytic effector molecule.

Authors:  P Anderson
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

5.  Human papillomavirus and lower genital neoplasia in renal transplant patients.

Authors:  R Halpert; R G Fruchter; A Sedlis; K Butt; J G Boyce; F H Sillman
Journal:  Obstet Gynecol       Date:  1986-08       Impact factor: 7.661

6.  Biological-clinical significance of selective loss of HLA-class-I allelic product expression in squamous-cell carcinoma of the uterine cervix.

Authors:  S Honma; S Tsukada; S Honda; M Nakamura; K Takakuwa; T Maruhashi; S Kodama; K Kanazawa; T Takahashi; K Tanaka
Journal:  Int J Cancer       Date:  1994-06-01       Impact factor: 7.396

7.  The ability of transforming growth factor-beta 1 to preferentially inhibit the induction of cytotoxicity in human T cells is determined by the nature of the activating signals.

Authors:  J Xie; G Gallagher
Journal:  Anticancer Res       Date:  1994 Jul-Aug       Impact factor: 2.480

Review 8.  Granzymes, a family of serine proteases released from granules of cytolytic T lymphocytes upon T cell receptor stimulation.

Authors:  D E Jenne; J Tschopp
Journal:  Immunol Rev       Date:  1988-03       Impact factor: 12.988

9.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

10.  Perforin and serine esterase gene expression in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A.

Authors:  C C Liu; S Rafii; A Granelli-Piperno; J A Trapani; J D Young
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  16 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 2.  Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies.

Authors:  John Berry; Sean C Glasgow
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

3.  Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.

Authors:  Dai-Wei Liu; Yuh-Cheng Yang; Ho-Fan Lin; Mei-Fang Lin; Ya-Wen Cheng; Chen-Chung Chu; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

4.  Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.

Authors:  Jo-Ann S Passmore; Michelle Milner; Lynnette Denny; Candice Sampson; Dianne J Marais; Bruce Allan; Pam P Gumbi; Inga I Hitzeroth; Edward P Rybicki; Anna-Lise Williamson
Journal:  Immunology       Date:  2006-10-09       Impact factor: 7.397

5.  Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable.

Authors:  Xuelian Wang; Anna-Barbara Moscicki; Laura Tsang; Andrea Brockman; Mayumi Nakagawa
Journal:  Clin Vaccine Immunol       Date:  2008-04-30

Review 6.  Therapy of human papillomavirus-related disease.

Authors:  Peter L Stern; Sjoerd H van der Burg; Ian N Hampson; Thomas R Broker; Alison Fiander; Charles J Lacey; Henry C Kitchener; Mark H Einstein
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

7.  Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes.

Authors:  T D de Gruijl; H J Bontkes; F Peccatori; M P Gallee; T J Helmerhorst; R H Verheijen; J Aarbiou; W M Mulder; J M Walboomers; C J Meijer; N van de Vange; R J Scheper
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

8.  Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas.

Authors:  I Cruz; C J Meijer; J M Walboomers; P J Snijders; I Van der Waal
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

9.  Immunotherapy of human papilloma virus induced disease.

Authors:  Sjoerd H van der Burg
Journal:  Open Virol J       Date:  2012-12-28

10.  Role of zinc and alpha2 macroglobulin on thymic endocrine activity and on peripheral immune efficiency (natural killer activity and interleukin 2) in cervical carcinoma.

Authors:  E Mocchegiani; A Ciavattini; L Santarelli; A Tibaldi; M Muzzioli; P Bonazzi; R Giacconi; N Fabris; G G Garzetti
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.